Clinical Trials

Arrhythmogenic cardiomyopathy

Displaying 3 studies

Assessing Pre-existing Antibodies To AAV In A Population Of Patients With PKP2-Associated ARVC Rochester, MN

The purpose of this multicenter, seroprevalence study to assess pre-existing antibodies to Adenovirus-associated Virus Vector (AAV) in a population of patients with Plakophilin 2 (PKP2)-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), who may be eligible for subsequent gene therapy trials. Biological samples and clinical data will be collected over a period of up to 5 years from the date of enrollment. No investigational product will be administered.
TN-401, A Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Plakophilin-2 (PKP2) Transgene, In Adults With PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Rochester, MN

The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-401 in adult patients with symptomatic PKP2 mutation-associated ARVC. The trial will consist of 2 escalating dose cohorts. All patients will receive active drug.
Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy Rochester, MN

The purpose of this study is to identify hereditary causes of cardiomyopathy.